Hennion & Walsh Asset Management Inc. Acquires 47,824 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 139.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,057 shares of the biotechnology company's stock after purchasing an additional 47,824 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.30% of Arcturus Therapeutics worth $1,393,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Arcturus Therapeutics during the third quarter worth $42,000. China Universal Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after purchasing an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Arcturus Therapeutics in the 2nd quarter worth about $142,000. Point72 DIFC Ltd purchased a new position in Arcturus Therapeutics during the 2nd quarter valued at about $188,000. Finally, SG Americas Securities LLC bought a new stake in shares of Arcturus Therapeutics during the third quarter valued at about $191,000. Institutional investors and hedge funds own 94.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reissued a "buy" rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of "Buy" and a consensus target price of $66.75.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT traded down $0.22 during mid-day trading on Friday, reaching $16.79. The stock had a trading volume of 225,175 shares, compared to its average volume of 370,806. The stock has a market capitalization of $454.84 million, a P/E ratio of -7.56 and a beta of 2.63. Arcturus Therapeutics Holdings Inc. has a one year low of $14.30 and a one year high of $45.00. The firm has a 50 day moving average price of $17.46 and a two-hundred day moving average price of $19.85.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. During the same period last year, the company earned ($0.61) EPS. Research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.31 earnings per share for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.